ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3161

Rates of Hospitalization for Infection and Related Mortality By Race/Ethnicity and Sex Among Patients with End-Stage Renal Disease Due to Systemic Lupus Erythematosus

Candace H. Feldman1, Francisco M. Marty2, Wolfgang C. Winkelmayer3, Hongshu Guan4, Jessica M. Franklin5, Seoyoung C. Kim6, Daniel H. Solomon7 and Karen H. Costenbader8,9, 1Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Department of Medicine, Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, 3Medicine-Nephrology, Baylor College of Medicine, Houston, TX, 4Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 5Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, 6Medicine, Division of Rheumatology, Division of Pharmacoepidemiology, Brigham & Women's Hospital, Boston, MA, 7Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, 8Rheumatology, Brigham & Women's Hospital, Boston, MA, 9Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Infection, Lupus, morbidity and mortality and renal disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Epidemiology and Public Health IV: Risk Factors and Comorbidities for SLE and Psoriatic Arthritis

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose:
Infections are a significant cause of morbidity and mortality in SLE patients.
Recent studies show that lupus nephritis patients have more than two-fold
higher incidence of serious infections than the overall SLE population. We
investigated the burden of hospitalized infections and related mortality among
patients with SLE-related end-stage renal disease (ESRD).

Methods:
We
used the US Renal Data System, the national registry of ESRD patients, 1995-2008,
to identify adults ≥18 years with ESRD due to SLE as recorded by nephrologists
on the Medical Evidence Report. We ascertained age, sex, race/ethnicity, region,
comorbidities, prior insurance, and dialysis type at ESRD onset. For patients
with Medicare Parts A and B coverage beginning 90 days following ESRD onset, we
used linked claims to determine hospitalizations for infection from primary discharge
diagnosis ICD-9 codes. We calculated mortality due to infection, as documented
on the ESRD Death Notification Form, among patients with SLE-related ESRD
regardless of Medicare coverage. We calculated incidence rates (IR) of first hospitalization
for infection after ESRD onset, and mortality due to infection. We used multivariable
Cox proportional hazard regression to determine the hazard ratio (HR) of first
hospitalized infection and mortality from infection by race/ethnicity and sex,
adjusting for demographics, comorbidities, and dialysis type.

Results: We
identified 12,533 patients with SLE-related ESRD and 6,064 with linked Medicare
claims. The mean age for the linked cohort was 41.8 years (SD 16.5), 81% were
female, 52.4% Black, 42.3% White, and 4.2% Asian, and 15.2% were Hispanic. Mean
follow-up was 4.0 years (SD 3.3). The majority (84%) received hemodialysis. The
IR of first hospitalization for infection after ESRD onset was 25.9 per 100
person-years. In adjusted models, the risk was lower among males compared to
females (HR 0.83, 95% CI 0.76-0.91) and higher among Blacks (HR 1.16, 95% CI
1.11-1.27) and Native Americans (HR 1.40, 95% CI 1.04-1.88) compared to Whites.
The risk of infection was higher among patients receiving peritoneal dialysis
compared to hemodialysis (HR 1.19, 95% CI 1.07-1.32). Among all patients with
SLE-related ESRD, there were 4,428 deaths; 865 (19.5%) were from infection, the
majority from septicemia (79.9%). Infection-related mortality was 1.77 per 100
person-years, significantly higher among Blacks compared to Whites (HR 1.20,
95% CI 1.02-1.42), and not statistically different for other racial/ethnic
groups or by sex.

Conclusion:
In
this cohort of patients with SLE-related ESRD, we observed a high burden of
hospitalization for infection and related mortality with similar infection
rates to pre-ESRD lupus nephritis patients. Female, Black and Native American
patients were at increased risk of infection. Further studies are needed to
compare these rates to non-SLE patients with ESRD.

Table. Incidence Rates and Adjusted Hazard Ratios of First Hospitalized Infection* among patients with SLE-Related End-stage Renal Disease and Medicare Parts A and B

Events

Person-years

IR** (95% CI)

HR+ (95% CI)

Overall (N=6064)

3496

13498.1

25.9 (25.1-26.7)

—

Sex

Female

2913

10762.3

27.1 (26.1-28.1)

Ref.

Male

583

2735.8

21.3 (19.6-23.1)

0.83 (0.76-0.91)

Race/Ethnicity

White

1344

5710.0

23.5 (22.3-24.8)

Ref.

Black

1982

6964.9

28.4 (27.2-29.7)

1.16 (1.11-1.27)

Asian

123

694.3

17.7 (14.8-21.1)

0.88 (0.72-1.07)

Native American

47

129.0

36.4 (27.4-48.5)

1.40 (1.04-1.88)

Hispanic Ethnicity

Hispanic

531

2299.0

23.1 (21.2-25.1)

1.01 (0.90-1.13)

Non-Hispanic

2965

11199.1

26.4 (25.5-27.4)

Ref.

*Primary discharge diagnosis with ICD-9 code for bacterial, viral, fungal or opportunistic infection (Schneeweiss et al. J Clin Epidemiol. 2007)

**Incidence rate of first hospitalized infection per 100 person-years

+Hazard ratios from Cox proportional hazard regression models adjusted for age group, sex, race/ethnicity, US region, insurance status prior to ESRD, baseline comorbidities including hypertension, smoking, diabetes, coronary artery disease, cerebrovascular disease, cancer, and COPD, renal replacement therapy, and calendar year


Disclosure: C. H. Feldman, None; F. M. Marty, None; W. C. Winkelmayer, None; H. Guan, None; J. M. Franklin, None; S. C. Kim, Pfizer Inc, 2,AstraZeneca, 2,Lilly, 2,Genentech and Biogen IDEC Inc., 2; D. H. Solomon, None; K. H. Costenbader, None.

To cite this abstract in AMA style:

Feldman CH, Marty FM, Winkelmayer WC, Guan H, Franklin JM, Kim SC, Solomon DH, Costenbader KH. Rates of Hospitalization for Infection and Related Mortality By Race/Ethnicity and Sex Among Patients with End-Stage Renal Disease Due to Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/rates-of-hospitalization-for-infection-and-related-mortality-by-raceethnicity-and-sex-among-patients-with-end-stage-renal-disease-due-to-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rates-of-hospitalization-for-infection-and-related-mortality-by-raceethnicity-and-sex-among-patients-with-end-stage-renal-disease-due-to-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology